Use Of Benralizumab For Patients With Moderate To Severe Atopic Dermatitis Despite Treatment With Topical Medications
Posted Date: Nov 17, 2020
- Investigator: Debra Breneman
- Specialties:
- Type of Study: Drug
Atopic dermatitis (AD) is a chronic inflammatory disease. The lack of approved treatments for AD has led to recommendations for use of other agents not approved for AD. There is therefore, an unmet medical need for more effective long-term treatments for AD that would target both local and systemic immune activation. Benralizumab is a monoclonal antibody that binds to the interleukin-5 receptor, a known participant of inflammatory and immune responses in AD. The study will evaluate the efficacy and safety of benralizumab in individuals with moderate to severe AD who remained symptomatic despite treatment with topical medication. The study involves a 16-week placebo-controlled treatment period, followed by a 36-week period of benralizumab extension period when all participants will receive the drug.
Criteria:
Eligible Subjects Must Have Documented History Of Atopic Dermatitis That Is Not Adequately Controlled With Topical Medications; Easi Score >12; Iga>3; Bsa Involvement >10%; Agree To Apply Moisturizer During The Duration Of The Study; Willing To Comply Wi
Keywords:
Moderate-Severe Atopic Dermatitis, Monoclonal Antibody, Placebo-Controlled Study
For More Information:
Jordan Perry
513-558-0945
perryj8@ucmail.uc.edu